Séminaire médico-scientifique CRCL/CLB
Le prochain séminaire médico-scientifique CRCL/CLB se tiendra le vendredi 27janvier à 11h30 dans la salle ONCORA (Centre Léon Bérard, 2e étage). Nous serons heureux d'accueillir Patricia Kannouche (Genome Stability and Oncogenesis, UMR8200, Gustave Roussy, Villejuif) pour un séminaire intitulé : "Cross-talk between DNA Replication Stress and Immune Response: Role of the E3 Ligase Rad18…and beyond."
Le 3e Symposium CRCL 2017 vous donne rendez-vous les 25-27 septembre 2017 ! Découvrez le nouveau site web dédié en cliquant ici.
The 1st International Symposium "Immune Responses in Cancer and Infection" jointly organized by the CRCL and the CIRI (International Research Centre in Infectiology) will take place in Lyon, February 13-15 2017 ! See you soon there ! Information and program : click here
Plusieurs postes sont à pourvoir au CRCL : cliquez ici
Postdoc in tumor immunology: click here
- Other postdoc positions are available in the teams of M. Gabut and J. Marie: click here
Poste d'IE (CDD 2 ans) en immuno-oncologie : cliquez ici
Postdoc in the G. Ichim's team : click here
Stage M2 Recherche en Immuno-oncologie (profil recherché : Interne en Anatomopathologie) : cliquez ici (réponse avant le 15/01)
A postdoc position in the team of F. Zoulim : click here
- poste d'ingénieur d'étude ou AI en immunomarquage : cliquez ici
- A 2 year post-doctoral position is available in the Team "Nuclear Domains and Pathologies" to work on an ANR funded project on Pancreatic Cancer Research. Click here
- A short-term (CDD) technical position is available at the Immunomonitoring platform: click here
- 1 postdoc position is available in the team of F. Zoulim, supervised by D. Durantel and J. Lucifora. Click here
- A Computational Biologist/Immunology position is available in the team of C. Caux and JY Blay. click here
Suivez les actualités du CRCL sur notre compte Twitter !
ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors
mardi 22 mars 2016
This work involved the team of Alain Puisieux.
Targeted therapies with MAPK inhibitors (MAPKi) are faced with severe problems of resistance in BRAF-mutant melanoma. In parallel to the acquisition of genetic mutations, melanoma cells may also adapt to the drugs through phenotype switching. The ZEB1 transcription factor, a known inducer of EMT and invasiveness, is now considered as a genuine oncogenic factor required for tumor initiation, cancer cell plasticity, and drug resistance in carcinomas. Here, we show that high levels of ZEB1 expression are associated with inherent resistance to MAPKi in BRAFV600-mutated cell lines and tumors.
PubMed access: click here
Structural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical Implications in Cancers
vendredi 25 mars 2016
This study involves the team of Patrick Mehlen.
Netrin-1 has been shown to be up-regulated in a fraction of human cancers as a mechanism to allow these tumors to escape the pro-apoptotic activity of some of its main dependence receptors, the UNC5 homologs (UNC5H). Here we identify the V-2 domain of netrin-1 to be important for its interaction with the Ig1/Ig2 domains of UNC5H2. We generate a humanized anti-netrin-1 antibody that disrupts the interaction between netrin-1 and UNC5H2 and triggers death of netrin-1-expressing tumor cells in vitro. We also present evidence that combining the anti-netrin-1 antibody with epidrugs such as decitabine could be effective in treating tumors showing no or modest netrin-1 expression. These results support that this antibody is a promising drug candidate.
PubMed access: click here